Adagene Inc. (ADAG)
NASDAQ: ADAG · Real-Time Price · USD
3.850
+0.020 (0.52%)
At close: Jul 9, 2026, 4:00 PM EDT
3.850
0.00 (0.00%)
After-hours: Jul 9, 2026, 4:10 PM EDT
Adagene Employees
Adagene had 128 employees as of December 31, 2025. The number of employees decreased by 10 or -7.25% compared to the previous year.
Employees
128
Change (1Y)
-10
Growth (1Y)
-7.25%
Revenue / Employee
$59,929
Profits / Employee
-$137,574
Market Cap
254.38M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 128 | -10 | -7.25% |
| Dec 31, 2024 | 138 | -36 | -20.69% |
| Dec 31, 2023 | 174 | -74 | -29.84% |
| Dec 31, 2022 | 248 | -11 | -4.25% |
| Dec 31, 2021 | 259 | 61 | 30.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Entrada Therapeutics | 152 |
| Coherus Oncology | 145 |
| AC Immune | 122 |
| Invivyd | 122 |
| Niagen Bioscience | 117 |
| Fulcrum Therapeutics | 55 |
| Surrozen | 44 |
| Anavex Life Sciences | 34 |
ADAG News
- 7 weeks ago - Adagene Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 7 weeks ago - Adagene Slides: Investor presentation - Filings
- 2 months ago - Adagene to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Adagene presents data from two Phase 1b/2 studies of muzastotug at AACR - TheFly
- 2 months ago - Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types - GlobeNewsWire
- 3 months ago - Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board - GlobeNewsWire
- 3 months ago - Adagene price target raised to $10 from $9 at Guggenheim - TheFly
- 3 months ago - Adagene Slides: Investor presentation - Filings